IPP Bureau
Tislelizumab plus chemo show promising results for esophageal cancer in Phase III study
By IPP Bureau - April 27, 2022
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Syngene full-year revenue from operations up 19% to Rs. 2604 crore
By IPP Bureau - April 27, 2022
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Dr Mandaviya calls for innovation in the pharma and medical devices
By IPP Bureau - April 26, 2022
The minister was speaking at the 7th International conference on Pharma and Medical Devices sector; chairs two roundtable conferences with the CEOs
Malaysia awards three-year contract for Biocon Biologics’ Insugen
By IPP Bureau - April 26, 2022
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
USFDA approves first Covid-19 treatment for young children
By IPP Bureau - April 26, 2022
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Pharming gets positive review from UK MHRA for leniolisib
By IPP Bureau - April 26, 2022
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Biocytogen signs RenMab/RenLite licensing agreement with BeiGene
By IPP Bureau - April 26, 2022
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Lonza and Integral Molecular partner on biotherapeutics
By IPP Bureau - April 26, 2022
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
USFDA clears Franklin Mountain Medical's new dual catheter
By IPP Bureau - April 26, 2022
It enables precise visualization and treatment access to the left heart
Roche and Fitterfly co-create 90-day diabetes programme
By IPP Bureau - April 26, 2022
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
SRL Diagnostics opens state-of-the-art laboratory in Jamshedpur
By IPP Bureau - April 26, 2022
The new lab in the industrial town is SRL’s 4th lab in the state of Jharkhand
Sygnature Discovery acquires Peak Proteins
By IPP Bureau - April 26, 2022
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
GSK launches once daily, single inhaler-triple therapy for COPD patients
By IPP Bureau - April 26, 2022
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Differentiation based on innovation is the way forward: S Aparna
By IPP Bureau - April 26, 2022
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
Drugs Controller clears Covaxin, Corbevax and ZyCov-D for kids
By IPP Bureau - April 26, 2022
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
